Clinical trials: Early Alzheimer's Disease
Dementia, Alzheimer Disease
Integrating eSAGE With EHR Data Using Machine Learning for the Early Detection and Monitoring of Cognitive Impairment in Individuals
The goal of this observational trial is to leverage the electronic Self-Administered Gerocognitive Examination (eSAGE), a variety of metadata (a set of data that describes and gives information about other data) collected during…
- Conditions
- Dementia, Alzheimer Disease, Mild Cognitive Impairment, Worried Well
- Trial name
- NCT06017505
- Testing
- electronic self administered gerocognitive examination (eSAGE)
- Where
- United States
- Volunteers
- 1,486 people
- Sponsor
- Douglas Scharre
Dementia
Research on the Early and Prognosis Diagnosis of Vascular Dementia
Around 10% of stroke survivors develop dementia within 3 months after stroke and over 20% more stroke patients have dementia in the subsequent 3 years.
- Trial name
- NCT03152630
- Where
- Taiwan
- Volunteers
- 600 people
- Sponsor
- National Taiwan University Hospital
Alzheimer's Disease, Mild Cognitive Impairment
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected…
- Trial name
- NCT05040217
- Testing
- AAV2-BDNF Gene Therapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mark Tuszynski
AD, Early Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment [MCI] due to AD, or…
- Trial name
- NCT07252440
- Testing
- TTYP01 tables 60mg, TTYP01 tables 90mg, TTYP01 tables 0mg
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
Alzheimer s Disease, Alzheimer Dementia (AD)
Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs
This research proposal outlines a multi-center, randomized, trial. Patients diagnosed with early-to-moderate Alzheimer's Disease will be recruited. Participants will be randomly assigned to receive either Lecanemab.
- Conditions
- Alzheimer s Disease, Alzheimer Dementia (AD), MCI-AD, Early Stage Alzheimer's Disease
- Trial name
- NCT07604896
- Testing
- Lecanemab 10 mg/kg, Conventional anti-dementia treatment group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Alzheimer Disease, Mild Cognitive Impairment
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
- Trial name
- NCT05469360
- Testing
- NIO752
- Where
- 10 sites in Finland, France and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Amyloidosis, Amyloid
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.
- Conditions
- Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy
- Trial name
- MED-hATTR (NCT03431896)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The Cleveland Clinic
Alzheimer's Disease
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group study using a Bayesian design with response adaptive randomization across placebo or 5 active arms of lecanemab to determine clinical efficacy…
- Trial name
- NCT01767311
- Testing
- Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg
- Where
- 169 sites in United States, Canada and 9 more
- Volunteers
- 856 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
Measurement of Retinal Nerve Fiber Layer Thickness - a Biomarker for the Early Detection of Alzheimer's Disease?
The purpose of this study is to determine whether by measuring changes in the thickness of the retinal nerve fibre layer (the photosensitive layer at the back of the eye) you could predict if someone would develop Alzheimer's…
- Trial name
- SCI-OCT (NCT02051244)
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Carmel Medical Center
Alzheimer Disease
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort.
- Trial name
- NCT04437511
- Testing
- Donanemab
- Where
- 274 sites in United States, Australia and 7 more
- Volunteers
- 1,736 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Lecanemab for Early Onset Familial Alzheimer's Disease
The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD.
- Trial name
- NCT06883019
- Where
- 15 sites in China
- Volunteers
- 114 people
- Sponsor
- RenJi Hospital
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT04623242)
- Testing
- Gantenerumab, Solanezumab
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.
Alzheimer Disease, Parkinson Disease
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study.
- Trial name
- NCT04524351
- Testing
- Posiphen
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Annovis Bio Inc.
Alzheimer Disease, Mild Cognitive Impairment
Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease
This study investigates the effects of Valaciclovir treatment to individuals with Alzheimer's disease or Mild Cognitive Impairment of Alzheimer's Disease Type.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Herpes Simplex
- Trial name
- VALZ-Pilot (NCT02997982)
- Testing
- Valaciclovir 500Mg Tablet
- Where
- 2 sites in Sweden
- Volunteers
- 33 people
- Sponsor
- Hugo Lovheim
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer's Disease
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).
- Trial name
- TARBELA-AD (NCT07781657)
- Testing
- RO7568282
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Hoffmann-La Roche
Mild Cognitive Impairment, Cognitive Impairment
SNIFF - 3-Week Aptar CPS Device
The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body.
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease, Early Onset
- Trial name
- NCT05006599
- Testing
- Insulin (Humulin® R U-100), Aptar Pharma CPS Intranasal Delivery Device
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Alzheimer's Disease
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
Approximately 90 patients, aged 50 to 80 years, with a diagnosis of early Alzheimer's disease will take part in this research study. This study will be conducted in the US.
- Trial name
- EAD501 (NCT05607615)
- Testing
- Hydroxypropyl Beta Cyclodextrin
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Cyclo Therapeutics, Inc.
Alzheimer Disease
Olfactory Neuroepithelial Tissue of Alzheimer Disease
The purpose of this study is to evaluate the olfactory neuroepithelium as a biomarker of Alzheimer disease. The early diagnosis of Alzheimer disease is of importance for obtaining better response to treatment, but recently…
- Trial name
- NCT02129452
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital